| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1008901133 |
| P356 | DOI | 10.1007/S40257-016-0205-5 |
| P698 | PubMed publication ID | 27371134 |
| P2093 | author name string | Lisa A Beck | |
| Diane Wang | |||
| P2860 | cites work | Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. | Q53536137 |
| Inadequate response to ustekinumab in atopic dermatitis - a report of two patients. | Q53668118 | ||
| Activation of TLR2 enhances tight junction barrier in epidermal keratinocytes. | Q54567889 | ||
| Induction of beta-defensin 3 in keratinocytes stimulated by bacterial lipopeptides through toll-like receptor 2. | Q54601882 | ||
| Toll-like receptor 2 (TLR2) mediates intracellular signalling in human keratinocytes in response to Malassezia furfur. | Q54631753 | ||
| Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis | Q56772998 | ||
| Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma | Q24681031 | ||
| The role of microorganisms in atopic dermatitis | Q24683941 | ||
| Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics | Q26799532 | ||
| Barrier Epithelial Cells and the Control of Type 2 Immunity | Q26801045 | ||
| Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches | Q26852335 | ||
| Functional activity of serotoninergic and melatoninergic systems expressed in the skin | Q28206451 | ||
| Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice | Q28265772 | ||
| IL-31: a new link between T cells and pruritus in atopic skin inflammation | Q28295839 | ||
| IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis | Q28295850 | ||
| Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis | Q28303063 | ||
| Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis | Q30525640 | ||
| Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies | Q30957004 | ||
| Cost of atopic dermatitis and eczema in the United States | Q33183415 | ||
| Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. | Q33799732 | ||
| Molecular mechanisms of IgE regulation | Q33835041 | ||
| Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. | Q33849441 | ||
| Exome sequencing of filaggrin and related genes in African-American children with atopic dermatitis | Q33916764 | ||
| Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6) | Q33916807 | ||
| Filaggrin mutations associated with skin and allergic diseases. | Q34223419 | ||
| Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis | Q34229692 | ||
| Anti-immunoglobulin E in the treatment of refractory atopic dermatitis | Q34307177 | ||
| Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate | Q34486040 | ||
| Proteases as Th2 adjuvants | Q34662936 | ||
| Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects | Q34782224 | ||
| Structures and biological functions of IL-31 and IL-31 receptors | Q34858355 | ||
| Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate | Q35048395 | ||
| Atopic dermatitis: a disease of altered skin barrier and immune dysregulation | Q35065037 | ||
| Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies | Q35077866 | ||
| Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents | Q35539576 | ||
| Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib | Q35800753 | ||
| Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis | Q35877149 | ||
| Functions of thymic stromal lymphopoietin in immunity and disease | Q35953900 | ||
| Mechanistic correlations between two itch biomarkers, cytokine interleukin-31 and neuropeptide β-endorphin, via STAT3/calcium axis in atopic dermatitis | Q36351112 | ||
| T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements. | Q36503230 | ||
| Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6 | Q36509379 | ||
| Activation of epidermal toll-like receptor 2 enhances tight junction function: implications for atopic dermatitis and skin barrier repair | Q36692559 | ||
| A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults | Q36734928 | ||
| Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases | Q36775280 | ||
| Climatic factors are associated with childhood eczema prevalence in the United States. | Q36821478 | ||
| "Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis. | Q37137538 | ||
| Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4. | Q37175971 | ||
| Cathelicidin deficiency predisposes to eczema herpeticum | Q37307447 | ||
| Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study | Q37375523 | ||
| A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. | Q37397800 | ||
| Cellular and molecular mechanisms in atopic dermatitis | Q37499326 | ||
| IL-5- and eosinophil-mediated inflammation: from discovery to therapy | Q37612636 | ||
| A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. | Q37649820 | ||
| Extrinsic and intrinsic types of atopic dermatitis | Q37703808 | ||
| Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. | Q37709674 | ||
| Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis | Q37709681 | ||
| Type 2 innate immune responses and the natural helper cell. | Q37842599 | ||
| Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts | Q37855007 | ||
| The cutaneous innate immune response in patients with atopic dermatitis. | Q38078473 | ||
| Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. | Q38104457 | ||
| Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review | Q38165590 | ||
| Type 2 Innate Lymphoid Cells in Allergic Disease | Q38216020 | ||
| IL-17 and infections | Q38268322 | ||
| The JAK-STAT pathway: impact on human disease and therapeutic intervention | Q38317993 | ||
| Emerging biologics for the treatment of chronic rhinosinusitis | Q38344266 | ||
| Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). | Q38411653 | ||
| Type 2 cytokines: mechanisms and therapeutic strategies | Q38424752 | ||
| Interleukin 4 inhibition as a potential therapeutic in pemphigus | Q38600160 | ||
| Targeting key proximal drivers of type 2 inflammation in disease | Q38608260 | ||
| Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis | Q38958215 | ||
| The Toll-like receptor 2 R753Q mutation modifies cytokine production and Toll-like receptor expression in atopic dermatitis | Q40018839 | ||
| IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. | Q40109996 | ||
| Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial | Q40445632 | ||
| Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. | Q40672713 | ||
| The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis | Q40682613 | ||
| Endogenous antimicrobial peptides and skin infections in atopic dermatitis | Q40698186 | ||
| Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis | Q41719738 | ||
| Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab | Q42575535 | ||
| Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis | Q42639324 | ||
| Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses | Q42944667 | ||
| Dysregulation of CD36 upon TLR-2 stimulation in monocytes from patients with atopic dermatitis and the TLR2 R753Q polymorphism | Q43256713 | ||
| OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study | Q43692258 | ||
| Effects of an anti-TSLP antibody on allergen-induced asthmatic responses | Q44096664 | ||
| The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma. | Q44102880 | ||
| Association of the toll-like receptor 2 A-16934T promoter polymorphism with severe atopic dermatitis | Q44413966 | ||
| Dupilumab in persistent asthma with elevated eosinophil levels | Q44480181 | ||
| Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study | Q44696806 | ||
| Novel filaggrin mutation but no other loss-of-function variants found in Ethiopian patients with atopic dermatitis. | Q44971096 | ||
| Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study | Q46098786 | ||
| Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma | Q46413563 | ||
| Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. | Q46424938 | ||
| Prevalence of IgE-mediated food allergy among children with atopic dermatitis. | Q46629938 | ||
| Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions | Q46637522 | ||
| Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma | Q47265833 | ||
| Differential in vivo cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT-PCR. | Q47341670 | ||
| Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes | Q47640250 | ||
| The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, plac | Q47933206 | ||
| The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype | Q47984267 | ||
| Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial | Q48099089 | ||
| Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions | Q50232370 | ||
| Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. | Q52870118 | ||
| Quality of life in atopic dermatitis. | Q53480974 | ||
| P433 | issue | 5 | |
| P921 | main subject | atopic dermatitis | Q268667 |
| P304 | page(s) | 425-443 | |
| P577 | publication date | 2016-07-01 | |
| P1433 | published in | American Journal of Clinical Dermatology | Q18616212 |
| P1476 | title | Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update | |
| P478 | volume | 17 |
| Q47383323 | A safety review of the medications used to treat atopic dermatitis |
| Q45601105 | Atopic Dermatitis in Animals and People: An Update and Comparative Review |
| Q47602738 | Atopic Dermatitis: Disease Background and Risk Factors |
| Q50057530 | Atopic dermatitis physiopathology |
| Q64993836 | Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology. |
| Q50094027 | Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis |
| Q55074071 | Emollient treatment of atopic dermatitis: latest evidence and clinical considerations. |
| Q26739986 | Molecular Mechanisms of Cutaneous Inflammatory Disorder: Atopic Dermatitis |
| Q54110780 | Severe Atopic Dermatitis in Children. |
| Q47880524 | The Future of Atopic Dermatitis Treatment |
| Q33838470 | Therapeutic Applications of Rose Hips from Different Rosa Species. |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.